Potential Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients With Chronic Myeloid Leukemia in a VA Regional Network
Federal Practitioner · 01.05.2026 · 43 (Suppl 2)
DOI: 10.12788/fp.0714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Federal Practitioner, online erschienen am 01.05.2026. Verfasst von Kirsten Werner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Sierra Nevada Health Care System, Reno. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Veterans Affairs Sierra Nevada Health Care System, Reno.
- Veterans Integrated Service Network 21, Pleasant Hill, California.
- Veterans Affairs Palo Alto Health Care System, California.
- Veterans Integrated Services Network 9, Nashville, Tennessee.
Zitieren
APA
Werner, K., Carmichael, J., Flynn, S., Huberman, D., Malmstrom, R., Higgins, D. T., & Taylor, J. M. (2026). Potential Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients With Chronic Myeloid Leukemia in a VA Regional Network. Federal Practitioner, 43(Suppl 2). https://doi.org/10.12788/fp.0714
Vancouver
Werner K, Carmichael J, Flynn S, Huberman D, Malmstrom R, Higgins DT, et al. Potential Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients With Chronic Myeloid Leukemia in a VA Regional Network. Federal Practitioner. 2026;43(Suppl 2). doi:10.12788/fp.0714
BibTeX
@article{Werner2026,
author = {Werner, Kirsten and Carmichael, Jenna and Flynn, Steve and Huberman, David and Malmstrom, Robert and Higgins, Diana T and Taylor, Janice M},
title = {Potential Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients With Chronic Myeloid Leukemia in a VA Regional Network},
journal = {Federal Practitioner},
year = {2026},
volume = {43},
number = {Suppl 2},
doi = {10.12788/fp.0714}
}
EUVIMED